Presentation and evolution of positive COPD patients

7 views 0 05/20/2020

  1. Systemic symptoms such as fever and fatigue are often predominant compared to an acute exacerbation where cough, sputum and dyspnea appear first6.
  2. People older than 60 years with comorbidity like COPD are more susceptibility to contract SARS-CoV-21.
  3. According to a meta analysis of 3403 cases, COPD is one of the most prevalent underlying diseases among hospitalized COVID-19 patients3.
  4. Higher mortality rates were observed when COPD patients developing COVID-191,2.
  5. Worse clinical outcomes are seen in patients who have preexisting comorbidities like chronic obstructive pulmonary disease (COPD)1,2,4.
    • In a study of 1590 COVID-19 hospitalized patients in China, 62,5% were considered severe cases2 and 50% were either being admitted to the intensive care unit, needing invasive ventilation or dead2.
  6. A significantly higher risk of exacerbation of COVID-19 infection is seen in patients with COPD as a comorbidity4.
  7. Patients with COPD have a 5.9% higher risk of progression in their disease than patients without this comorbidity4.
  8. Case-fatality is estimated at 1-2% of all cases. Nearly all cases resulting in death were patients with significant underlying chronic diseases including COPD and cardiovascular diseases5.

 

Ji HL., et al present a review to summarize the existence of elevated plasminogen in patients with comorbidities infected by COVID-19. Guan WJ., et al present an Early View to analyze patients with comorbidities et their risk of serious adverse outcomes. This study included 1590 laboratory-confirmed hospitalized patients. Emami A., et al have written a meta-analysis to estimate the prevalence of underlying disease with confirmed and hospitalized COVID-19 patients. 3403 cases have been used for the analysis. Wang B., et al present a meta-analysis to explore if the presence of certain comorbidities increases the risk of developing COVID-19 infection. 1558 cases were included in 6 different studies. Leung JM., et al present a Research letter to determine if patients with COPD have increased expression of ACE-2 which is the cellular entry receptor for SARS-CoV-2. Jie Z., et al present a medical instruction for management and prevention of COPD during the COVID-19 epidemic period.

 

Sources : 

  1. Ji HL., Zhao R., Matalon S., et al. (March 27, 2020). Elevated Plasmin(ogen) as a Common Risk Factor for Covid-19 Susceptibility. Physiological Reviews, American Physiological Society. https://doi.org/10.1152/physrev.00013.2020
  2. Guan WJ., Liang WH., Zhao Y., et al. (March 26, 2020). Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. European Respiratory Journal. Doi: 1183/13993003.00547-2020
  3. Emami A., Javanmardi F., Pirbonyeh N., et al. (March 24, 2020). Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis. Archive of Academics Emergency Medicine. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7096724/
  4. Wang B., Li R., Lu Z., et al. (April 8, 2020). Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Impact Journal, Aging US. https://paperchase-aging.s3-us-west-1.amazonaws.com/pdf/qv4macXM3ESBdrCdp.pdf
  5. Leung JM., Yang CX., Tam A., et al. (April 8, 2020). ACE-2 Expression in the Small Airway Epithelia of Smokers and COPD Patients: Implications for COVID-19. European Respiratory journal. DOI:1183/13993003.00688-2020
  6. Jie Z., Hu HH., Zhi Z., et al. (March 10, 2020). Medical management and prevention instruction of chronic obstructive pulmonary disease during the coronavirus disease 2019 epidemic. DOI: 10.3760/cma.j.cn112147-20200227-00201

 

Tags:

Was this helpful?

 
Related Articles